Dacomitinib/Dacomitinib usage guidelines and detailed explanations

1. Introduction to dacomitinib

Dacomitinib/Dacomitinib (Dacomitinib), as a drug for the treatment of specific lung cancer, has been widely studied and has achieved significant efficacy in suitable patients.

2. Applicable groups and indications

Dacomitinib is mainly suitable for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation confirmed by testing methods approved by the U.S. Food and Drug Administration (FDA).

3. Possible side effects

There may be some side effects from using dacomitinib. Common ones include diarrhea, rash, paronychia, stomatitis, loss of appetite, dry skin, weight loss, hair loss, cough and itching. Serious side effects may include severe diarrhea and interstitial lung disease. If you feel unwell, seek medical attention immediately.

4. Medication guidance

The recommended dose of dacomitinib is 45 mg orally once daily and should be continued until disease progression or unacceptable toxicity occurs. The medicine can be taken with food or on an empty stomach, but be sure to take it at the same time every day. If you miss a dose due to vomiting or other reasons, it is not recommended to take the next dose as originally planned.

5. Drug storage methods

Dacomitinib is available in tablet form and should be stored at a temperature of 20°C to 25°C (68°F to 77°F), with an allowed temperature excursion of 15°C to 30°C (59°F to 86°F).

6. Drug action mechanism

Dacomitinib works by irreversibly inhibiting the kinase activity of the human EGFR family (including EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations. In addition, it inhibits the activities of DDR1, EPHA6, LCK, DDR2 and MNK1 at clinically relevant concentrations in vitro, showing dose-dependent inhibition of EGFR and HER2 autophosphorylation as well as tumor growth.

7. Risk of overdose

In animal studies, dacomitinib has been shown to potentially induce embryo-fetotoxicity. In addition, overdose may lead to toxic reactions such as stomatitis, rash, palmar-plantar dysesthesia syndrome, dehydration, paronychia, and diarrhea. The maximum tolerated dose has been determined to be 45 mg. If overdose is suspected, seek medical attention immediately.

8. Taboo groups

Pregnant and lactating women: Because dacomitinib may cause damage to the fetus, it is recommended that women of childbearing potential take effective contraceptive measures and avoid breastfeeding during treatment and for at least 17 days after discontinuation of treatment.